KR20160055728A - Her2 결합제의 용도 - Google Patents
Her2 결합제의 용도 Download PDFInfo
- Publication number
- KR20160055728A KR20160055728A KR1020157036172A KR20157036172A KR20160055728A KR 20160055728 A KR20160055728 A KR 20160055728A KR 1020157036172 A KR1020157036172 A KR 1020157036172A KR 20157036172 A KR20157036172 A KR 20157036172A KR 20160055728 A KR20160055728 A KR 20160055728A
- Authority
- KR
- South Korea
- Prior art keywords
- her2
- seq
- tracer
- tumor
- absorption
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361840021P | 2013-06-27 | 2013-06-27 | |
US61/840,021 | 2013-06-27 | ||
PCT/SE2014/050774 WO2014209205A1 (en) | 2013-06-27 | 2014-06-24 | Use of her2 binders |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20160055728A true KR20160055728A (ko) | 2016-05-18 |
Family
ID=52142378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020157036172A KR20160055728A (ko) | 2013-06-27 | 2014-06-24 | Her2 결합제의 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10646600B2 (de) |
EP (1) | EP3014277A4 (de) |
JP (1) | JP2016526556A (de) |
KR (1) | KR20160055728A (de) |
CN (1) | CN105579851A (de) |
BR (1) | BR112015032211A2 (de) |
WO (1) | WO2014209205A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160055728A (ko) | 2013-06-27 | 2016-05-18 | 지이 헬쓰케어 리미티드 | Her2 결합제의 용도 |
JP7097636B2 (ja) * | 2017-06-20 | 2022-07-08 | ナノマブ テクノロジー リミテッド | 抗Her2ナノボディ及びそのコード序列と用途 |
CN108434469A (zh) * | 2018-05-29 | 2018-08-24 | 江苏省原子医学研究所 | 一种HER2亲合体的68Ga标记物及其制备方法、应用 |
CN110251695B (zh) * | 2019-07-10 | 2021-12-21 | 莎穆(上海)生物科技有限公司 | 一种靶向her2的放射性配合物及其制备方法和应用 |
KR102502287B1 (ko) * | 2020-04-17 | 2023-02-22 | 앱클론(주) | 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체 |
CN114317385B (zh) * | 2021-11-11 | 2024-02-13 | 元本(珠海横琴)生物科技有限公司 | 一种促进her2亲和体蛋白分泌表达的发酵培养基及发酵工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007024940A2 (en) * | 2005-08-22 | 2007-03-01 | Dana-Farber Cancer Institute, Inc. | Mitochondrial localization of muc1 |
US8303960B2 (en) * | 2007-02-27 | 2012-11-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radiolabeled affibody molecules |
EP2072525A1 (de) * | 2007-12-21 | 2009-06-24 | Affibody AB | Neue Polypeptide mit Bindungsaffinität für HER2 |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
US20120165650A1 (en) | 2010-12-22 | 2012-06-28 | General Electric Company | Her2 binders |
EP2400992B1 (de) * | 2009-02-27 | 2015-07-22 | Genentech, Inc. | Verfahren und zusammensetzungen zur kennzeichnung von proteinen |
US20150283272A1 (en) * | 2010-10-27 | 2015-10-08 | Vikas Kundra | Dual mode gadolinium nanoparticle contrast agents |
EP2661284A1 (de) | 2010-12-22 | 2013-11-13 | GE Healthcare UK Limited | Mit einer 18f-haltigen siliziumorganischen verbindung markierte her2-bindende peptide |
CA3159948A1 (en) | 2010-12-22 | 2012-07-19 | General Electric Company | Radiolabled her2 binding peptides |
KR20160055728A (ko) | 2013-06-27 | 2016-05-18 | 지이 헬쓰케어 리미티드 | Her2 결합제의 용도 |
-
2014
- 2014-06-24 KR KR1020157036172A patent/KR20160055728A/ko not_active Application Discontinuation
- 2014-06-24 US US14/900,841 patent/US10646600B2/en active Active
- 2014-06-24 BR BR112015032211A patent/BR112015032211A2/pt not_active IP Right Cessation
- 2014-06-24 JP JP2016523697A patent/JP2016526556A/ja active Pending
- 2014-06-24 EP EP14816932.9A patent/EP3014277A4/de not_active Withdrawn
- 2014-06-24 CN CN201480036224.6A patent/CN105579851A/zh active Pending
- 2014-06-24 WO PCT/SE2014/050774 patent/WO2014209205A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112015032211A2 (pt) | 2017-08-29 |
JP2016526556A (ja) | 2016-09-05 |
US20160144062A1 (en) | 2016-05-26 |
US10646600B2 (en) | 2020-05-12 |
EP3014277A1 (de) | 2016-05-04 |
CN105579851A (zh) | 2016-05-11 |
WO2014209205A1 (en) | 2014-12-31 |
EP3014277A4 (de) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160055728A (ko) | Her2 결합제의 용도 | |
Munnink et al. | 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft | |
JP6666905B2 (ja) | Pd−l1抗体及びその使用 | |
Reilly et al. | Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody | |
McLarty et al. | Associations between the uptake of 111 In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts | |
KR20220015445A (ko) | 항체-약물 접합체의 투약 | |
Wei et al. | PET imaging of receptor tyrosine kinases in cancer | |
CA3160557A1 (en) | Treatment of cancer | |
US10517966B2 (en) | Anti-human MUC1 antibody Fab fragment | |
Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
Mankoff et al. | Development of companion diagnostics | |
CN107613974B (zh) | 抗-met抗体及其使用方法 | |
Terwisscha van Scheltinga et al. | Preclinical efficacy of an antibody–drug conjugate targeting mesothelin correlates with quantitative 89Zr-immunopet | |
Trousil et al. | Positron Emission Tomography Imaging with 18F-Labeled Z HER2: 2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies | |
Turker et al. | An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis | |
AU2018333290A1 (en) | AXL-specific antibodies and uses thereof | |
KR20100072194A (ko) | 항종양 약물의 분류 마커로서 ed―b 피브로넥틴 | |
CA3149872A1 (en) | Methods of treating kras mutant cancers | |
JP2017503763A (ja) | Gcc発現細胞を撮像するための化合物及び組成物 | |
Subbiah et al. | Phase I study of P-cadherin–targeted radioimmunotherapy with 90Y-FF-21101 monoclonal antibody in solid tumors | |
Burvenich et al. | Receptor occupancy imaging studies in oncology drug development | |
Kim et al. | Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2) | |
Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine | |
Schmitz et al. | Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck | |
US20220372125A1 (en) | Antigen Specific Binding Domains and Antibody Molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |